AnGes, Inc. (FRA:AJW)

Germany · Delayed Price · Currency is EUR

0.1610

+0.0060 (3.87%)

Last updated: Aug 26, 2026, 8:01 AM CET

-61.48% (1Y)

Market Cap	83.77M -52.6%
Revenue (ttm)	5.18M +35.5%
Net Income	-20.85M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	566
Open	0.1610
Previous Close	0.1550
Day's Range	0.1610 - 0.1610
52-Week Range	0.1550 - 0.6150
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About AnGes

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan. [Read more]

Industry Pharmaceutical Preparations

Founded 1999

Employees 56

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol AJW

Financial Performance

In 2025, AnGes's revenue was 874.00 million, an increase of 35.93% compared to the previous year's 643.00 million. Losses were -5.12 billion, -81.79% less than in 2024.

Financial numbers in JPY Financial Statements